CN113480667B - Human granulocyte colony stimulating factor mutant recombinant fusion protein and preparation method and application thereof - Google Patents
Human granulocyte colony stimulating factor mutant recombinant fusion protein and preparation method and application thereof Download PDFInfo
- Publication number
- CN113480667B CN113480667B CN202110941810.7A CN202110941810A CN113480667B CN 113480667 B CN113480667 B CN 113480667B CN 202110941810 A CN202110941810 A CN 202110941810A CN 113480667 B CN113480667 B CN 113480667B
- Authority
- CN
- China
- Prior art keywords
- csf
- protein
- mut
- rtbd1
- stimulating factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A recombinant fusion protein of human granulocyte colony stimulating factor mutant is prepared through connecting human granulocyte colony stimulating factor mutant and ricin B chain truncated peptide by flexible linker (Gly) 4 Ser) 3 A linker peptide. The preparation method of the human granulocyte colony stimulating factor mutant recombinant fusion protein comprises the following steps: constructing a human granulocyte colony stimulating factor mutation expression vector; constructing an escherichia coli recombinant expression vector; expressing the recombinant hG-CSF-Mut/RTBD1 fusion protein; purifying and renaturing the recombinant hG-CSF-Mut/RTBD1 fusion protein. The recombinant fusion protein has long half-life period and high biological activity, prolongs the half-life period, improves the biological activity, and reduces the granulocyte colony stimulating factor preparationThe production cost can be applied to the preparation of the medicine for treating leucopenia.
Description
Technical Field
The invention relates to the technical field of biological genetic engineering, in particular to a human granulocyte colony stimulating factor mutant recombinant fusion protein and a preparation method and application thereof.
Background
Granulocyte colony stimulating factor (G-CSF) is a glycoprotein that primarily acts on the proliferation, differentiation and activation of hematopoietic cells of the neutrophil lineage (linkage). The recombinant human granulocyte colony stimulating factor (rhG-CSF-Mut/RTBD 1) acts on hematopoietic progenitor cells to promote the proliferation and differentiation of the hematopoietic progenitor cells, and has the important functions of stimulating the maturation of granulocyte and monocyte macrophages, promoting the release of the mature cells to peripheral blood and promoting multiple functions of the macrophages and the eosinophilic cells. The G-CSF is mainly used for clinically preventing and treating leukopenia caused by tumor radiotherapy or chemotherapy, treating myelohematopoietic dysfunction and myelodysplastic syndrome, preventing infection complications possibly caused by leukopenia and accelerating recovery of neutropenia caused by infection. However, the granulocyte colony stimulating factor has the problems of short half-life period, easy degradation in vivo and the like in clinic, and the clinical application of the granulocyte colony stimulating factor is limited.
Ricin (RT) is covalently linked by two peptide chains, RTA and RTB, with a disulfide bond. Wherein RTB consists of 262 amino acids. RTB alone is not toxic. RTB is currently believed to have two main functions: 1. the RTA is facilitated to be transported into cytoplasm, and the protein synthesis is inhibited; 2. RTB enhances the immune response of the body.
At present, the research of improving the activity of the recombinant fusion protein for treating leukopenia and prolonging the half life of the recombinant fusion protein by combining the human G-CSF mutant and the ricin B chain truncated peptide into the recombinant fusion protein has not been reported.
Disclosure of Invention
The invention provides a human granulocyte colony stimulating factor mutant recombinant fusion protein, a preparation method and application thereof, which are used for improving the activity of the recombinant fusion protein in treating leukopenia, prolonging the half-life period of the recombinant fusion protein and improving the treatment effect of the leukopenia.
The technical scheme adopted by the invention for solving the technical problem is as follows:
the invention relates to a human granulocyte colony stimulating factor mutant recombinant fusion protein which is formed by connecting a human granulocyte colony stimulating factor mutant and ricin B chain truncated peptide through a flexible linker.
As a preferred embodiment, the human granulocyte colony stimulating factor mutant is prepared by the following steps: designing a site-directed mutagenesis primer, mutating the 19 th leucine to tryptophan and the 28 th aspartic acid to arginine in a human granulocyte colony-stimulating factor sequence by taking a recombinant plasmid pUC57-hG-CSF as a template, and naming the mutated sequence as hG-CSF-Mut;
the sequence of the site-directed mutagenesis primer is as follows:
SiteⅠ
Forward:5'-GAGTTTTCTGCTGAAATGCTGGGAACAGGTTCGTAAAATT C-3';
Reverse:5'-GAATTTTACGAACCTGTTCCCAGCATTTCAGCAGAAAACTC-3';
SiteⅡ
Forward:5'-GTAAAATTCAGGGTAGGGGCGCAGCCCTGCAG-3';
Reverse:5'-CTGCAGGGCTGCGCCCCTACCCTGAATTTTAC-3'。
as a preferred embodiment, the mutated hG-CSF-Mut sequence and the ricin B chain truncated peptide sequence are connected by a flexible linker to form the hG-CSF-Mut/RTBD1 sequence, the nucleotide sequence of which is shown as SEQ ID NO. 1, and the amino acid sequence of which is shown as SEQ ID NO. 2.
As a preferred embodiment, the flexible linker is (Gly) 4 Ser) 3 A linker peptide.
The invention relates to a preparation method of a human granulocyte colony stimulating factor mutant recombinant fusion protein, which comprises the following steps:
step one, constructing a human granulocyte colony stimulating factor mutation expression vector;
constructing an escherichia coli recombinant expression vector;
step three, expressing the recombinant hG-CSF-Mut/RTBD1 fusion protein;
and step four, purifying and renaturing the recombinant hG-CSF-Mut/RTBD1 fusion protein.
As a preferred embodiment, the step one specifically comprises the following steps:
(1) Carrying out homologous modeling on human granulocyte colony stimulating factor molecules and human granulocyte colony stimulating factor receptor molecules through a SWISS-MODEL online platform; docking the human granulocyte colony stimulating factor molecules and the human granulocyte colony stimulating factor receptor molecules by a Z-DOCK method to obtain a compound structure model; mutating the full-length sequence of the compound structure model by alanine scanning to obtain potential mutation sites; calculating intermolecular binding force change before and after mutation on a single mutation site through virtual saturation mutation;
(2) Preparation of recombinant plasmid pUC 57-hG-CSF:
inquiring a human granulocyte colony stimulating factor gene sequence through an NCBI Genbank database, carrying out whole-gene synthesis on the obtained sequence, carrying out codon optimization by using codon preference of escherichia coli in the synthesis process, and cloning the sequence into an escherichia coli cloning vector pUC57 to obtain an escherichia coli recombinant cloning vector pUC57-hG-CSF;
(3) Designing a site-directed mutagenesis primer, wherein the sequence of the site-directed mutagenesis primer is as follows:
SiteⅠ
Forward:5'-GAGTTTTCTGCTGAAATGCTGGGAACAGGTTCGTAAAATT C-3';
Reverse:5'-GAATTTTACGAACCTGTTCCCAGCATTTCAGCAGAAAACTC-3';
SiteⅡ
Forward:5'-GTAAAATTCAGGGTAGGGGCGCAGCCCTGCAG-3';
Reverse:5'-CTGCAGGGCTGCGCCCCTACCCTGAATTTTAC-3';
(4) The 19 th leucine in the sequence of the human granulocyte colony-stimulating factor is mutated into tryptophan and the 28 th aspartic acid in the sequence of the human granulocyte colony-stimulating factor by taking the recombinant plasmid pUC57-hG-CSF as a template, and the mutated sequence is named as hG-CSF-Mut; the mutated hG-CSF-Mut sequence and the ricin B chain truncated peptide sequence are connected through a flexible linker to form an hG-CSF-Mut/RTBD1 sequence, the nucleotide sequence is shown as SEQ ID NO. 1, the amino acid sequence is shown as SEQ ID NO. 2, the hG-CSF-Mut/RTBD1 sequence is inserted into a pMD18T vector, and a product with correct sequencing is named as a pMD18T-hG-CSF-Mut/RTBD1 plasmid and serves as an hG-CSF mutation expression vector.
As a preferred embodiment, the second step specifically comprises the following steps:
carrying out double enzyme digestion on the pMD18T-hG-CSF-Mut/RTBD1 plasmid and the pET30a vector with correct sequencing respectively, wherein the reaction system and conditions are shown in Table 1, and carrying out gel recovery on double enzyme digestion products; connecting the two products obtained after the glue is recovered by using T4 ligase, wherein the connection system and conditions are shown in table 1;
TABLE 1
Name of reagent | Dosage of |
T4 DNA Ligase | 1μL |
10×T4 DNA Ligase Bμffer | 4μL |
Recovered hG-CSF target fragment | 4μL |
Recovered pET30a vector fragment | 1μL |
Reaction conditions | Overnight at 16 deg.C |
Transforming the ligation product into a Trans10 competent cell; after conversion, coated to a final concentration of 100. Mu.g/mL Kan + After overnight culture, selecting a plurality of white single colonies with good growth vigor, carrying out amplification culture and carrying out PCR; the positive plasmids identified by PCR were subjected to sequencing analysis.
As a preferred embodiment, the step three specifically includes the following steps:
inoculating correctly sequenced positive bacteria BL21 (DE 3)/pET 30a-hG-CSF-Mut/RTBD1 into 5mL LB culture medium containing Kan with the concentration of 100 mu g/mL according to the proportion of 1; adding IPTG to the induction group until the final concentration is 1mmol/L, and oscillating at constant temperature of 180rpm at 37 ℃ for induction for 16h; after 16h of induction, the bacterial precipitation rhG-CSF-Mut/RTBD1 is obtained by centrifugation at 8000rpm and 4 ℃.
As a preferred embodiment, the step four specifically comprises the following steps:
(1) Ion exchange chromatography: balancing a Q column by using a protein purification A liquid, performing denaturing dissolution on the rhG-CSF/RTBD1 inclusion body by using the protein purification A liquid, loading a dissolved solution on the column, and collecting a flow-through liquid, wherein the target protein exists in the flow-through liquid; adjusting the salt ion concentration of the flow-through solution to 0.5mol/L for the next step of metal chelating chromatography;
(2) Metal chelating chromatography: pair of Ni-loaded proteins with protein-purified B solution 2+ Balancing by using a chemical Sepharose; loading rhG-CSF-Mut/RTBD1 solution purified by ion exchange chromatography to a column, mixing protein purification solution C and protein purification solution D by a gradient mixing module in a protein purification system, eluting chelating Sepharose by imidazole with final concentration of 50mmol/L and 250mmol/L respectively, and collecting protein flow-through solution, hybrid protein solution and target protein solution respectively; subjecting the protein solution collected in each step to SDS-PAGE analysis with a gel concentration of 12%;
(3) rhG-CSF-Mut/RTBD1 protein renaturation: diluting the rhG-CSF-Mut/RTBD1 protein solution purified by the two steps by using protein renaturation A solution until the concentration of the rhG-CSF-Mut/RTBD1 is 0.1mg/mL, filling the rhG-CSF-Mut/RTBD1 solution into a protein ultrafiltration system with the molecular weight cutoff of 3000 to carry out dialysis renaturation, and adding protein renaturation B solution into the protein ultrafiltration system; regulating the rotating speed of a peristaltic pump in the protein ultrafiltration system and the tightness degree of a liquid outlet valve to keep the protein concentration speed consistent with the liquid inlet speed of the liquid B; the protein renaturation process is carried out at 4 ℃, and the whole process is carried out for 48-72 h, so as to meet the requirements of thorough removal of urea and slow and sufficient folding of rhG-CSF-Mut/RTBD1 protein; after the protein renaturation B liquid is drained, protein renaturation C liquid is introduced to remove residual cane sugar and glycerin components in the renaturation process, rhG-CSF-Mut/RTBD1 protein is concentrated to the concentration of 1-1.5 mg/mL, and recombinant hG-CSF-Mut/RTBD1 fusion protein is obtained;
the composition of the protein purification solution A is as follows: 50mmol/L PB,8mol/L Urea, pH 6.0;
the composition of the protein purification solution B is as follows: 50mmol/L PB,8mol/L Urea,0.5mol/L NaCl pH 6.0;
the composition of the protein purification solution C is as follows: 50mmol/L Tris,8mol/L Urea,0.5mol/L NaCl, pH 8.0;
the composition of the protein purification solution D is as follows: 50mmol/L Tris,8mol/L Urea,0.5mol/L NaCl,500mmol/L Imidazole, pH 8.0;
the protein renaturation A liquid comprises the following components: 50mmol/L Tris,8mol/L Urea,10% m/v sucrose, 10% v/v glycerol, 5mmol/L DTT, pH 8.0;
the composition of the protein renaturation B liquid is as follows: 50mmol/L Tris,10% m/v sucrose, 10% v/v glycerol, pH 8.0;
the protein renaturation C solution comprises the following components: 50mmol/L Tris, pH 8.0.
The invention relates to an application of a human granulocyte colony stimulating factor mutant recombinant fusion protein in preparing a medicament for treating leukopenia.
The invention has the beneficial effects that:
the invention relates to a recombinant fusion protein of a human granulocyte colony stimulating factor mutant, which is prepared from the human granulocyte colony stimulating factor mutantIs connected with ricin B chain truncated peptide through a flexible linker. Wherein the flexible linker is (Gly) 4 Ser) 3 A linker peptide. Compared with the common human granulocyte colony stimulating factor, the human granulocyte colony stimulating factor mutant recombinant fusion protein has the advantages of long half-life period, high biological activity and the like.
The human granulocyte colony stimulating factor mutant recombinant fusion protein can be applied to preparing medicaments for treating leukopenia, and has great potential and value in development of medicaments for treating leukopenia and veterinary clinical application.
Drawings
FIG. 1 is a schematic diagram of human granulocyte colony-stimulating factor (hG-CSF) before and after mutation.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
EXAMPLE 1 preparation of recombinant hG-CSF-Mut/RTBD1 fusion protein
1. Construction of human granulocyte colony-stimulating factor (hG-CSF) mutant expression vector
(1) Carrying out homologous modeling on human granulocyte colony stimulating factor molecules and human granulocyte colony stimulating factor receptor molecules through an SWISS-MODEL online platform; docking the human granulocyte colony stimulating factor molecules and the human granulocyte colony stimulating factor receptor molecules by a Z-DOCK method to obtain a compound structure model; mutating the full-length sequence of the compound structure model by alanine scanning to obtain potential mutation sites; the intermolecular binding force changes before and after mutation were calculated for a single mutation site by virtual saturation mutation.
(2) Preparation of recombinant plasmid pUC 57-hG-CSF:
querying a human granulocyte colony stimulating factor gene sequence through an NCBI Genbank database, carrying out whole-gene synthesis on the obtained sequence, carrying out codon optimization according to the codon preference of escherichia coli in the synthesis process, and cloning the sequence into an escherichia coli cloning vector pUC57 to obtain an escherichia coli recombinant cloning vector pUC57-hG-CSF.
(3) Designing a site-directed mutagenesis primer, wherein the sequence of the site-directed mutagenesis primer is as follows:
SiteⅠ
Forward:5'-GAGTTTTCTGCTGAAATGCTGGGAACAGGTTCGTAAAATT C-3';
Reverse:5'-GAATTTTACGAACCTGTTCCCAGCATTTCAGCAGAAAACTC-3';
Site Ⅱ
Forward:5'-GTAAAATTCAGGGTAGGGGCGCAGCCCTGCAG-3';
Reverse:5'-CTGCAGGGCTGCGCCCCTACCCTGAATTTTAC-3'。
(4) As shown in figure 1, recombinant plasmid pUC57-hG-CSF is used as a template, leucine at position 19 in a human granulocyte colony stimulating factor sequence is mutated into tryptophan, aspartic acid at position 28 in the human granulocyte colony stimulating factor sequence is mutated into arginine, so that the stability and the antiviral activity of the human granulocyte colony stimulating factor/RTBD 1 fusion protein are enhanced, and the mutated sequence is named as hG-CSF-Mut. Connecting the mutated hG-CSF-Mut sequence with a ricin B chain truncated peptide sequence (RTBD 1 sequence, the nucleotide sequence of which is shown as SEQ ID NO:3 in the sequence table, and the amino acid sequence of which is shown as SEQ ID NO:4 in the sequence table) by a flexible linker to form an hG-CSF-Mut/RTBD1 sequence, the nucleotide sequence of which is shown as SEQ ID NO:1 and the amino acid sequence of which is shown as SEQ ID NO:2, inserting the hG-CSF-Mut/RTBD1 sequence into a pMD18T vector, and after sequencing, naming a product with correct sequencing as: pMD18T-hG-CSF-Mut/RTBD1 plasmid, as hG-CSF mutation expression vector, for downstream genetic engineering operation. Wherein the adopted flexible linker is (Gly) 4 Ser) 3 A linker peptide.
2. Construction of recombinant expression vector for Escherichia coli
The pMD18T-hG-CSF-Mut/RTBD1 plasmid and the pET30a vector which are correctly sequenced are subjected to double enzyme digestion respectively, the reaction system and conditions are shown in Table 1, and the double enzyme digestion products are subjected to gel recovery. The two products after gel recovery were ligated using T4 ligase, and the ligation system and conditions are shown in table 1.
TABLE 1
Name of reagent | Dosage of |
T4 DNA Ligase | 1μL |
10×T4 DNA Ligase Bμffer | 4μL |
Recovered hG-CSF target fragment | 4μL |
Recovered pET30a vector fragment | 1μL |
Reaction conditions | 16 ℃ overnight |
The ligation products were transformed into Trans10 competent cells. After conversion, coated to a final concentration of 100. Mu.g/mL Kan + After overnight incubation, multiple white single colonies with good growth were picked, expanded and subjected to PCR. Sending the positive plasmid with correct PCR identification to Shanghai biological engineering technology service company Limited for sequencingAnd (6) analyzing.
3. Recombinant hG-CSF-Mut/RTBD1 fusion protein expression
Inoculating the positive bacterium BL21 (DE 3)/pET 30a-hG-CSF-Mut/RTBD1 with correct sequencing in 5mL LB culture medium containing 100 ug/mL Kan according to the ratio of 1; adding IPTG to the induction group until the final concentration is 1mmol/L, and oscillating at constant temperature of 180rpm at 37 ℃ for induction for 16h; after 16h of induction, the bacterial precipitation rhG-CSF-Mut/RTBD1 is obtained by centrifugation at 8000rpm and 4 ℃.
4. Purification and renaturation of recombinant hG-CSF-Mut/RTBD1 fusion protein
The bacterial pellet rhG-CSF-Mut/RTBD1 was purified using a two-step purification method. The purification method is carried out in the order of ion exchange chromatography and metal chelating chromatography, and comprises the following steps:
(1) Ion exchange chromatography: a Q column is balanced by using protein purification A liquid (50 mmol/L PB,8mol/L Urea, pH 6.0), rhG-CSF/RTBD1 inclusion bodies are subjected to denaturation dissolution by using the protein purification A liquid, a dissolved solution is loaded on the column, and a flow-through solution is collected, wherein the target protein mainly exists in the flow-through solution. The salt ion concentration of the flow-through was adjusted to 0.5mol/L for the next step of metal chelate chromatography.
(2) Metal chelating chromatography: loading with Ni was performed using protein purification B solution (50 mmol/L PB,8mol/L Urea,0.5mol/L NaCl pH 6.0) 2+ The equilibration was carried out on a chemical Sepharose. Loading rhG-CSF-Mut/RTBD1 solution purified by ion exchange chromatography on a column, mixing protein purification C solution (50 mmol/L Tris,8mol/L Urea,0.5mol/L NaCl, pH 8.0) and protein purification D solution (50 mmol/L Tris,8mol/L Urea,0.5mol/L NaCl,500mmol/L Imidazole, pH 8.0) by a gradient mixing module in a protein purification system, eluting chemical Sepharose by using Imidazole with final concentration of 50mmol/L and 250mmol/L respectively, and collecting protein flow-through solution, hetero protein solution and target protein solution respectively. The protein solution collected at each step was subjected to SDS-PAGE analysis with a gel concentration of 12%.
(3) rhG-CSF-Mut/RTBD1 protein renaturation: the rhG-CSF-Mut/RTBD1 protein solution purified in two steps was diluted with protein renaturation A solution (50 mmol/L Tris,8mol/L Urea,10% m/v sucrose, 10% v/v glycerol, 5mmol/L DTT, pH 8.0) to a rhG-CSF-Mut/RTBD1 concentration of 0.1mg/mL and charged into a protein ultrafiltration system having a molecular weight cut-off of 3000 for dialysis renaturation, and protein renaturation B solution (50 mmol/L Tris,10% m/v sucrose, 10% v/v glycerol, pH 8.0) was added to the protein ultrafiltration system. The rotating speed of a peristaltic pump in the protein ultrafiltration system and the tightness degree of a liquid outlet valve are adjusted, so that the protein concentration speed is consistent with the liquid inlet speed of the liquid B. The protein renaturation process is carried out at 4 ℃, and the whole process is carried out for 48-72 h, so as to meet the requirements of thorough removal of urea and slow and sufficient folding of the rhG-CSF-Mut/RTBD1 protein. And after the protein renaturation B liquid flows out, introducing protein renaturation C liquid (50 mmol/L Tris, pH 8.0) to remove components such as cane sugar and glycerol remained in the renaturation process, concentrating the rhG-CSF-Mut/RTBD1 protein until the concentration is 1-1.5 mg/mL, and obtaining the rhG-CSF-Mut/RTBD1 fusion protein.
EXAMPLE 2 pharmacodynamic assay of recombinant hG-CSF-Mut/RTBD1 fusion proteins
1. Construction of leukopenia mouse model
18 mice were selected and were injected intraperitoneally with 2 mg/day cyclophosphamide for three consecutive days. On the fourth day, whole blood from the mice was routinely assayed for white blood cell count (WBC). The model success criteria employed in this test were: the number of leukocytes is lower than the lowest value of the reference range by 0.8X 10 9 And L. The mice meeting the conditions prove that the preparation of the leukopenia mouse model is successful. The normal group and the model control group were subcutaneously administered with physiological saline the following day after the model creation, and the administration group was subcutaneously administered with 0.2. Mu.g of rhG-CSF-Mut/RTBD1 fusion protein to the neck and back of the mice the following day after the model creation.
TABLE 2 treatment of leukopenia with recombinant hG-CSF-Mut/RTBD1 fusion protein
Grouping animals | Number of animals | Group of | Administration mode | Administration of drugs |
1 | 6 | Normal group | Subcutaneous injection | Physiological saline |
2 | 6 | Model control group | Subcutaneous injection | Physiological saline |
3 | 6 | Administration set | Subcutaneous injection | rhG-CSF-Mut/RTBD1 |
2. Routine blood test
The number of leukocytes in the blood of mice was measured using a blood routine analyzer, and the results are shown in table 3.
TABLE 3 number of leukocytes for each group (n = 6)
As a result, the number of leukocytes was significantly increased compared with the model control group, and was restored to the reference range of normal mice (0.8X 10) 9 ~6.8×10 9 L), proving that the rhG-CSF-Mut/RTBD1 fusion protein of the invention successfully treats the leukopenia.
The invention discloses a human granulocyte colony stimulating factor mutant recombinant fusion protein, a preparation method and application thereof, and a person skilled in the art can realize the recombinant fusion protein by appropriately improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the invention has been described in terms of preferred embodiments, it will be apparent to those skilled in the art that the technology can be practiced and applied by modifying or appropriately combining the products described herein without departing from the spirit and scope of the invention.
Sequence listing
<110> Catharanthus roseus Biotech Ltd
<120> human granulocyte colony stimulating factor mutant recombinant fusion protein, preparation method and application thereof
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 993
<212> DNA
<213> Artificial (nucleotide)
<400> 1
atgcaccacc accaccacca cacccctctg ggccctgcaa gtagtctgcc gcagagtttt 60
ctgctgaaat gctgggaaca ggttcgtaaa attcagggta ggggcgcagc cctgcaggaa 120
aaactgtgtg caacctataa actgtgtcat ccggaagaac tggtgctgct gggccatagc 180
ctgggtattc cgtgggcccc gctgagcagc tgtccgtcac aggcactgca gctggccggt 240
tgtctgagtc agctgcatag cggcctgttt ctgtatcagg gcctgctgca ggcactggaa 300
ggtattagtc cggaactggg tccgaccctg gataccctgc agctggatgt tgccgatttt 360
gcaaccacca tttggcagca gatggaagaa ctgggtatgg ccccggccct gcagccgaca 420
cagggtgcaa tgccggcctt tgcaagtgca tttcagcgcc gtgccggcgg tgtgctggtt 480
gcaagccatc tgcagagttt tcttgaagtt agctatcgcg ttctgcgtca tctggcccag 540
ccgggcggtg gtggtagcgg tggtggtggt tcaggtggcg gtggtagcgc agatgtgtgt 600
atggatccgg aaccgattgt gcgcattgtg ggccgtaatg gtctgtgtgt ggatgtgcgt 660
gatggccgct ttcataatgg taatgccatt cagctgtggc cgtgtaaaag taataccgat 720
gccaatcagc tgtggaccct gaaacgcgat aataccattc gcagcaatgg taaatgtctg 780
accacctatg gttatagtcc gggtgtgtat gttatgatct atgattgcaa taccgccgca 840
accgatgcaa cccgctggca gatttgggat aatggcacca ttattaatcc gcgcagtagc 900
ctggttctgg ccgccaccag cggcaatagc ggtaccaccc tgaccgttca gaccaatatc 960
tatgcagtga gtcagggctg gctgccgacc aat 993
<210> 2
<211> 331
<212> PRT
<213> Artificial (Amino acids)
<400> 2
Met His His His His His His Thr Pro Leu Gly Pro Ala Ser Ser Leu
1 5 10 15
Pro Gln Ser Phe Leu Leu Lys Cys Trp Glu Gln Val Arg Lys Ile Gln
20 25 30
Gly Arg Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu
35 40 45
Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro
50 55 60
Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly
65 70 75 80
Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu
85 90 95
Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr
100 105 110
Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met
115 120 125
Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met
130 135 140
Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val
145 150 155 160
Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg
165 170 175
His Leu Ala Gln Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
180 185 190
Gly Gly Gly Ser Ala Asp Val Cys Met Asp Pro Glu Pro Ile Val Arg
195 200 205
Ile Val Gly Arg Asn Gly Leu Cys Val Asp Val Arg Asp Gly Arg Phe
210 215 220
His Asn Gly Asn Ala Ile Gln Leu Trp Pro Cys Lys Ser Asn Thr Asp
225 230 235 240
Ala Asn Gln Leu Trp Thr Leu Lys Arg Asp Asn Thr Ile Arg Ser Asn
245 250 255
Gly Lys Cys Leu Thr Thr Tyr Gly Tyr Ser Pro Gly Val Tyr Val Met
260 265 270
Ile Tyr Asp Cys Asn Thr Ala Ala Thr Asp Ala Thr Arg Trp Gln Ile
275 280 285
Trp Asp Asn Gly Thr Ile Ile Asn Pro Arg Ser Ser Leu Val Leu Ala
290 295 300
Ala Thr Ser Gly Asn Ser Gly Thr Thr Leu Thr Val Gln Thr Asn Ile
305 310 315 320
Tyr Ala Val Ser Gln Gly Trp Leu Pro Thr Asn
325 330
<210> 3
<211> 405
<212> DNA
<213> Artificial (nucleotide)
<400> 3
gcagatgtgt gtatggatcc ggaaccgatt gtgcgcattg tgggccgtaa tggtctgtgt 60
gtggatgtgc gtgatggccg ctttcataat ggtaatgcca ttcagctgtg gccgtgtaaa 120
agtaataccg atgccaatca gctgtggacc ctgaaacgcg ataataccat tcgcagcaat 180
ggtaaatgtc tgaccaccta tggttatagt ccgggtgtgt atgttatgat ctatgattgc 240
aataccgccg caaccgatgc aacccgctgg cagatttggg ataatggcac cattattaat 300
ccgcgcagta gcctggttct ggccgccacc agcggcaata gcggtaccac cctgaccgtt 360
cagaccaata tctatgcagt gagtcagggc tggctgccga ccaat 405
<210> 4
<211> 135
<212> PRT
<213> Artificial (Amino acids)
<400> 4
Ala Asp Val Cys Met Asp Pro Glu Pro Ile Val Arg Ile Val Gly Arg
1 5 10 15
Asn Gly Leu Cys Val Asp Val Arg Asp Gly Arg Phe His Asn Gly Asn
20 25 30
Ala Ile Gln Leu Trp Pro Cys Lys Ser Asn Thr Asp Ala Asn Gln Leu
35 40 45
Trp Thr Leu Lys Arg Asp Asn Thr Ile Arg Ser Asn Gly Lys Cys Leu
50 55 60
Thr Thr Tyr Gly Tyr Ser Pro Gly Val Tyr Val Met Ile Tyr Asp Cys
65 70 75 80
Asn Thr Ala Ala Thr Asp Ala Thr Arg Trp Gln Ile Trp Asp Asn Gly
85 90 95
Thr Ile Ile Asn Pro Arg Ser Ser Leu Val Leu Ala Ala Thr Ser Gly
100 105 110
Asn Ser Gly Thr Thr Leu Thr Val Gln Thr Asn Ile Tyr Ala Val Ser
115 120 125
Gln Gly Trp Leu Pro Thr Asn
130 135
Claims (7)
1. A recombinant fusion protein of a human granulocyte colony stimulating factor mutant is characterized in that the recombinant fusion protein is formed by connecting the human granulocyte colony stimulating factor mutant and a ricin B chain truncated peptide through a flexible linker;
the preparation process of the human granulocyte colony stimulating factor mutant comprises the following steps: designing a site-directed mutagenesis primer, taking a recombinant plasmid pUC57-hG-CSF as a template, and naming the mutated sequence as hG-CSF-Mut;
the sequence of the site-directed mutagenesis primer is as follows:
SiteⅠ
Forward:5'-GAGTTTTCTGCTGAAATGCTGGGAACAGGTTCGTAAAATTC-3';
Reverse:5'-GAATTTTACGAACCTGTTCCCAGCATTTCAGCAGAAAACTC-3';
SiteⅡ
Forward:5'-GTAAAATTCAGGGTAGGGGCGCAGCCCTGCAG-3';
Reverse:5'-CTGCAGGGCTGCGCCCCTACCCTGAATTTTAC-3';
and connecting the mutated hG-CSF-Mut sequence and the ricin B chain truncated peptide sequence by a flexible linker to form an hG-CSF-Mut/RTBD1 sequence, wherein the nucleotide sequence of the hG-CSF-Mut/RTBD1 is shown in SEQ ID NO. 1, and the amino acid sequence of the hG-CSF-Mut/RTBD1 is shown in SEQ ID NO. 2.
2. The method of claim 1, comprising the steps of:
step one, constructing a human granulocyte colony stimulating factor mutation expression vector;
constructing an escherichia coli recombinant expression vector;
step three, expressing the recombinant hG-CSF-Mut/RTBD1 fusion protein;
and step four, purifying and renaturing the recombinant hG-CSF-Mut/RTBD1 fusion protein.
3. The method for preparing human granulocyte colony stimulating factor mutant recombinant fusion protein as claimed in claim 2, wherein the first step specifically comprises the following steps:
(1) Carrying out homologous modeling on human granulocyte colony stimulating factor molecules and human granulocyte colony stimulating factor receptor molecules through an SWISS-MODEL online platform; docking the human granulocyte colony stimulating factor molecules and the human granulocyte colony stimulating factor receptor molecules by a Z-DOCK method to obtain a compound structure model; mutating the full-length sequence of the compound structure model by alanine scanning to obtain potential mutation sites; calculating intermolecular binding force change before and after mutation on a single mutation site through virtual saturation mutation;
(2) Preparation of recombinant plasmid pUC 57-hG-CSF:
inquiring a human granulocyte colony stimulating factor gene sequence through an NCBI Genbank database, carrying out whole-gene synthesis on the obtained sequence, carrying out codon optimization by using codon preference of escherichia coli in the synthesis process, and cloning the sequence into an escherichia coli cloning vector pUC57 to obtain an escherichia coli recombinant cloning vector pUC57-hG-CSF;
(3) Designing a site-directed mutagenesis primer, wherein the sequence of the site-directed mutagenesis primer is as follows:
SiteⅠ
Forward:5'-GAGTTTTCTGCTGAAATGCTGGGAACAGGTTCGTAAAATTC-3';
Reverse:5'-GAATTTTACGAACCTGTTCCCAGCATTTCAGCAGAAAACTC-3';
SiteⅡ
Forward:5'-GTAAAATTCAGGGTAGGGGCGCAGCCCTGCAG-3';
Reverse:5'-CTGCAGGGCTGCGCCCCTACCCTGAATTTTAC-3';
(4) The recombinant plasmid pUC57-hG-CSF is taken as a template, and the mutated sequence is named as hG-CSF-Mut; connecting the mutated hG-CSF-Mut sequence and a ricin B chain truncated peptide sequence by a flexible linker to form an hG-CSF-Mut/RTBD1 sequence, wherein the nucleotide sequence of the hG-CSF-Mut/RTBD1 is shown in SEQ ID NO:1, the amino acid sequence of the hG-CSF-Mut/RTBD1 is shown in SEQ ID NO:2, inserting the hG-CSF-Mut/RTBD1 sequence into a pMD18T vector, and naming the product with correct sequencing as a pMD18T-hG-CSF-Mut/RTBD1 plasmid as an hG-CSF mutation expression vector.
4. The method for preparing human granulocyte colony stimulating factor mutant recombinant fusion protein of claim 3, wherein the second step comprises the following steps:
carrying out double enzyme digestion on the pMD18T-hG-CSF-Mut/RTBD1 plasmid and the pET30a vector with correct sequencing respectively, and carrying out gel recovery on double enzyme digestion products; connecting the two products obtained after the glue is recovered by using T4 ligase; transforming the ligation product into a Trans10 competent cell; kan coated to final concentration of 100 mug/mL after conversion + After overnight culture, selecting a white single colony with good growth vigor, carrying out amplification culture and carrying out PCR (polymerase chain reaction); the positive plasmids identified by PCR were subjected to sequencing analysis.
5. The method for preparing human granulocyte colony stimulating factor mutant recombinant fusion protein of claim 4, wherein the third step comprises the following steps:
inoculating correctly sequenced positive bacteria BL21 (DE 3)/pET 30a-hG-CSF-Mut/RTBD1 into 5mL LB culture medium containing Kan with the concentration of 100 mug/mL according to the proportion of 1; adding IPTG to the induction group until the final concentration is 1mmol/L, and oscillating at constant temperature of 180rpm at 37 ℃ for induction for 16h; after 16h of induction, the bacterial precipitation rhG-CSF-Mut/RTBD1 is obtained by centrifugation at 8000rpm and 4 ℃.
6. The method for preparing human granulocyte colony stimulating factor mutant recombinant fusion protein of claim 5, wherein the fourth step comprises the following steps:
(1) Ion exchange chromatography: balancing a Q column by using a protein purification A liquid, performing denaturing dissolution on the rhG-CSF/RTBD1 inclusion body by using the protein purification A liquid, loading a dissolved solution on the column, and collecting a flow-through liquid, wherein the target protein exists in the flow-through liquid; adjusting the salt ion concentration of the flow-through solution to 0.5mol/L for the next step of metal chelating chromatography;
(2) Metal chelating chromatography: pair of Ni-Supported proteins with protein purification solution B 2+ Balancing by using chemical Sepharose; loading rhG-CSF-Mut/RTBD1 solution purified by ion exchange chromatography to a column, mixing protein purification solution C and protein purification solution D by a gradient mixing module in a protein purification system, eluting chelating Sepharose by imidazole with final concentration of 50mmol/L and 250mmol/L respectively, and collecting protein flow-through solution, hybrid protein solution and target protein solution respectively; performing SDS-PAGE analysis on the protein solution collected in each step, wherein the gel concentration is 12%;
(3) rhG-CSF-Mut/RTBD1 protein renaturation: diluting the rhG-CSF-Mut/RTBD1 protein solution purified in the two steps by using protein renaturation A liquid until the concentration of the rhG-CSF-Mut/RTBD1 is 0.1mg/mL, filling the rhG-CSF-Mut/RTBD1 protein solution into a protein ultrafiltration system with the molecular weight cutoff of 3000 for dialysis renaturation, and adding protein renaturation B liquid into the protein ultrafiltration system; regulating the rotating speed of a peristaltic pump in the protein ultrafiltration system and the tightness degree of a liquid outlet valve to keep the protein concentration speed consistent with the liquid inlet speed of the liquid B; the protein renaturation process is carried out at 4 ℃, and the whole process is carried out for 48 to 72h so as to meet the requirements of thorough removal of urea and slow and sufficient folding of rhG-CSF-Mut/RTBD1 protein; after the protein renaturation B liquid is drained, introducing the protein renaturation C liquid to remove residual cane sugar and glycerin components in the renaturation process, concentrating rhG-CSF-Mut/RTBD1 protein until the concentration is 1-1.5 mg/mL, and obtaining recombinant hG-CSF-Mut/RTBD1 fusion protein;
the composition of the protein purification solution A is as follows: 50mmol/L PB,8mol/L Urea, pH 6.0;
the composition of the protein purification solution B is as follows: 50mmol/L PB,8mol/L Urea,0.5mol/L NaCl pH 6.0;
the composition of the protein purification solution C is as follows: 50mmol/L Tris,8mol/L Urea,0.5mol/L NaCl, pH 8.0;
the composition of the protein purification solution D is as follows: 50mmol/L Tris,8mol/L Urea,0.5mol/L NaCl,500mmol/L Imidazole, pH 8.0;
the composition of the protein renaturation A solution is as follows: 50mmol/L Tris,8mol/L Urea,10% w/v sucrose, 10% v/v glycerol, 5mmol/L DTT, pH 8.0;
the composition of the protein renaturation B liquid is as follows: 50mmol/L Tris,10% m/v sucrose, 10% v/v glycerol, pH 8.0;
the protein renaturation C solution comprises the following components: 50mmol/L Tris, pH 8.0.
7. The use of the recombinant fusion protein of claim 1 in the preparation of a medicament for treating leukopenia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110941810.7A CN113480667B (en) | 2021-08-17 | 2021-08-17 | Human granulocyte colony stimulating factor mutant recombinant fusion protein and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110941810.7A CN113480667B (en) | 2021-08-17 | 2021-08-17 | Human granulocyte colony stimulating factor mutant recombinant fusion protein and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113480667A CN113480667A (en) | 2021-10-08 |
CN113480667B true CN113480667B (en) | 2023-03-28 |
Family
ID=77946653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110941810.7A Active CN113480667B (en) | 2021-08-17 | 2021-08-17 | Human granulocyte colony stimulating factor mutant recombinant fusion protein and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113480667B (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
DE102005002978B4 (en) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Recombinant expression of proteins in a disulfide-bonded, two-chain form |
EP1841787A2 (en) * | 2005-01-25 | 2007-10-10 | Cell Therapeutics, Inc. | Conjugates of biologically active proteins having a modified in vivo half-life |
CN102260343A (en) * | 2010-05-25 | 2011-11-30 | 健能隆医药技术(上海)有限公司 | Application of recombinant human G-CSF dimer for treating nerve damage disease |
WO2018114798A1 (en) * | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
BR112019014691A2 (en) * | 2017-01-18 | 2020-04-07 | Pieris Pharmaceuticals Gmbh | lipocalin muteins with binding affinity for lag-3 |
CN108864292B (en) * | 2018-06-27 | 2021-08-17 | 军事科学院军事医学研究院军事兽医研究所 | Interferon recombinant fusion protein and application thereof |
WO2020077136A1 (en) * | 2018-10-10 | 2020-04-16 | University Of Washington | Fusion products and bioconjugates containing mixed charge peptides |
-
2021
- 2021-08-17 CN CN202110941810.7A patent/CN113480667B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113480667A (en) | 2021-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101921329B (en) | Alpha interferon mutant and polyethylene glycol derivative thereof | |
CN101547935B (en) | Interferon alpha mutant and its polyethylene glycol derivative | |
CN102380090A (en) | G-CSF (granulocyte-colony stimulating factor) dimmer applied to treat neutropenia | |
CN110885379B (en) | Dog interferon mutant recombinant fusion protein and preparation method and application thereof | |
CN113527520A (en) | Cat granulocyte colony stimulating factor mutant recombinant fusion protein and preparation method and application thereof | |
CN113480667B (en) | Human granulocyte colony stimulating factor mutant recombinant fusion protein and preparation method and application thereof | |
CN103923209A (en) | Lambda interferon mutant and polyethylene glycol derivative | |
CN108840946A (en) | Dog albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of dog long-acting interferon | |
CN107286255A (en) | It is a kind of by OVA, chicken interferon gamma and chicken interferon α fusion protein constituted and preparation method thereof | |
CN101514229A (en) | Human interferon alpha derivative and polyethylene glycol modified substance thereof | |
CN109776653B (en) | Human serum albumin adhesion peptide and application thereof | |
CN113845599B (en) | Recombinant porcine interferon fusion protein and application thereof | |
CN113980142B (en) | Recombinant bovine interferon fusion protein and application thereof | |
CN113880956B (en) | Recombinant cat interferon fusion protein and preparation method and application thereof | |
CN108794644A (en) | A kind of fusion protein and preparation method thereof being made of cattle interleukins-2 2, Bov IFN γ and Bov IFN α | |
CN107400170A (en) | OVA interferon-' alpha ' interleukin-22 fusion protein, preparation method and its encoding gene, a breeder long-acting interferon | |
WO1985005619A1 (en) | Novel polypeptide and process for its preparation | |
CN117304344B (en) | Fusion protein, recombinant strain expressing fusion protein and application of recombinant strain | |
RU2515913C1 (en) | HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS) | |
CN107383202A (en) | A kind of fusion protein being made up of OVA, chicken interferon gamma and recombinant chIL-2 and preparation method thereof | |
CN103554246B (en) | Interferon alpha mutant and polyethylene glycol derivative thereof | |
CN107365390A (en) | A kind of fusion protein being made up of pig albumin, Porcine interferon-gamma and pig interleukin 2 and 6 and preparation method thereof | |
CN114920819A (en) | Recombinant human growth hormone mutant, polyethylene glycol derivative thereof, preparation method of polyethylene glycol derivative and pharmaceutical application of polyethylene glycol derivative | |
CN117384273A (en) | Polyethylene glycol modified IL-2 derivative and application thereof | |
CN108794643A (en) | A kind of fusion protein and preparation method thereof being made of dog albumin, dog interferon γ and canine leucocyte interleukin 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |